CClinicalTrials.gg
Sign In
Enrolling by invitationNCT06874894NOACUpdated Dec 29, 2025

Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

An observational study in Fibrillation, Atrial, sponsored by Chung-Ang University Hospital. Enrolling by invitation at 2 sites in South Korea. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Chung-Ang University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,021
Ages
18 Months and older
Sex
All
01

Study summary

This study was design to investigate the efficacy and safety of NOAC therapy in Koreans

Read the detailed description

East Asians have demonstrated a higher bleeding tendency compared to Western populations during an anticoagulation. Consequently, East Asians have been prescribed as a relatively weaker treatment regimens based on this evidence. Therefore, the TARGET-AF study aims to verify the efficacy and safety of NOAC therapy using biomarkers including TEG®-6S point-of-care device in Koreans

02

Conditions studied

  • Fibrillation, Atrial

Keywords

  • Atrial Fibrillation
  • Stroke
  • Bleeding
03

In context

Atrial Fibrillation

3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.

This study's planned enrollment of 1,021 is above the median of 300 across 1,363 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Chung-Ang University Hospital is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

AF patients with NOAC

Inclusion criteria

  • Patients with documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings are eligible for enrollment.
  • Based on AF treatment Korean guideline 19, AF patients who require NOAC treatment or are currently on NOAC treatment (within the past 3 months)
  • Adults aged 18 or above who have provided consent for clinical information

Exclusion criteria

Exclusion Criteria:

  • Patients with moderate or severe mitral stenosis or mechanical prosthetic valve
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,021 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Atrial Fibrillation

    Documented AF on 12-lead ECG, Holter monitoring, or single-lead ECG recordings and biomarkers using TEG®-6S with NOAC treatment

06

What researchers measure

Primary outcomes

  1. Clinical ischemic and hemorrhagic events

    The Rate of Ischemic stroke, systemic embolism, or myocardial infarction and ISTH (International Society on Thrombosis and Hemostasis) major/minor bleeding events

    Time frame: 12 months

Secondary outcomes

  1. Clinical other events

    The rate of Major Adverse Cardiovascular Events: Myocardial infarction, ischemic stroke, systemic embolism, and cardiovascular death (including bleeding).

    Time frame: 12 months

Other outcomes

  1. COVID-19 infection

    The rate of confirmation of COVID-19 infection and primary outcome

    Time frame: 12 months

07

Study locations

2 sites
  • Chung-Ang University Gwangmyeong Hospital
    Gwangmyeong, South Korea
  • Chung-Ang University Hospital
    Seoul, 06973, South Korea
08

References and documents

Publications

  • Lee SH, Kim HK, Ahn JH, Kang MG, Kim KH, Bae JS, Cho SY, Koh JS, Park Y, Hwang SJ, Gorog DA, Tantry US, Bliden KP, Gurbel PA, Hwang JY, Jeong YH. Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. Eur Heart J. 2023 May 14;44(19):1718-1728. doi: 10.1093/eurheartj/ehad088. PubMed 36857519 ↗

Individual participant data

Plan to share: Yes — CAUH 1992-002-387

Supporting information: Study protocol, Sap, Icf, Csr

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874894
Lead sponsor
Chung-Ang University Hospital
Collaborators
Chung-Ang University Gwangmyeong Hospital, Samsung Medical Center, Korea University Ansan Hospital, Kosin University Gospel Hospital, Keimyung University Dongsan Medical Center, Yuhan Corporation
Responsible party
Ki-Woon Kang (Associate Professor, Chung-Ang University Hospital) — Principal investigator
First posted
Mar 13, 2025
Start date
May 25, 2022
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Dec 29, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Atrial Fibrillation→

Other studies from this sponsor

Chung-Ang University Hospital

Start the discussion